Given the importance of leptin in driving obesity-breast cancer axis and the current lack of effective, clinically viable leptin-antagonists, it is imperative to develop novel leptin-antagonists that can potentially be utilized for clinical use. The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.